E’Ola Ephedrine Hydrochloride Sales Barred Under FDA Settlement
This article was originally published in The Tan Sheet
Executive Summary
FDA may order Biogenics, d/b/a E'Ola International, to "discontinue all manufacturing, processing, packing, labeling and distribution" if it believes the supplement marketer is selling a misbranded or adulterated product, according to a recent consent decree
You may also be interested in...
HHS/FDA Ephedra Strategy: A Risk Management Approach?
HHS Secretary Tommy Thompson is urging manufacturers of ephedrine alkaloid supplements to include FDA's MedWatch toll-free number on labeling to better enable consumer reporting of adverse events
HHS/FDA Ephedra Strategy: A Risk Management Approach?
HHS Secretary Tommy Thompson is urging manufacturers of ephedrine alkaloid supplements to include FDA's MedWatch toll-free number on labeling to better enable consumer reporting of adverse events
GMP Dispute Resolution System Under Development By FDA; PAT Is Impetus
FDA is planning to create a dispute resolution system for manufacturing inspections